Schedule of estimated useful lives of property, plant and equipment

The Company's property, plant, and equipment primarily consist of buildings, land, assembly equipment, molding machines, molds, office equipment, furniture, and fixtures. Depreciation and amortization are calculated using the straight-line method over the following useful lives:


Production equipment		3 to 13 years
Office furniture and equipment		3 to 10 years
Buildings		39 years
Building improvements		15 years

Schedule of disaggregated information of revenue recognized from contracts with customers and licensing fees recognized

Disaggregated information of revenue recognized from contracts with customers and licensing fees recognized are as follows:


	For the three months ended September 30, 2024:
			Blood						Total
			Collection		EasyPoint^®		Other		Product
Geographic Segment	Syringes		Products		Needles		Products		Sales
U.S. sales	$	4,470,036	$	290,926	$	4,860,327	$	7,319	$	9,628,608
North and South America sales (excluding U.S.)		569,970		—		—		—		569,970
Other international sales		132,817		7,790		3,572		4,100		148,279
Total	$	5,172,823	$	298,716	$	4,863,899	$	11,419	$	10,346,857


	For the three months ended September 30, 2023:
			Blood						Total
			Collection		EasyPoint^®		Other		Product
Geographic Segment	Syringes		Products		Needles		Products		Sales
U.S. sales	$	6,439,220	$	379,135	$	2,566,161	$	8,221	$	9,392,737
North and South America sales (excluding U.S.)		825,480		—		—		14,250		839,730
Other international sales		87,694		10,920		3,800		150		102,564
Total	$	7,352,394	$	390,055	$	2,569,961	$	22,621	$	10,335,031


	For the nine months ended September 30, 2024:
			Blood
			Collection		EasyPoint^®		Other			Total
Geographic Segment	Syringes		Products		Needles		Products			Revenue
U.S. sales	$	14,655,118	$	991,924	$	5,615,759	$	20,545	$	21,283,346
North and South America sales (excluding U.S.)		1,325,507		96		59,040		6,240		1,390,883
Other international revenue		961,429		151,650		178,276		10,000		1,301,355
Total	$	16,942,054	$	1,143,670	$	5,853,075	$	36,785	$	23,975,584


	For the nine months ended September 30, 2023:
			Blood						Total
			Collection		EasyPoint^®		Other		Product
Geographic Segment	Syringes		Products		Needles		Products		Sales
U.S. sales	$	17,022,384	$	1,123,808	$	3,944,284	$	26,385	$	22,116,861
North and South America sales (excluding U.S.)		5,596,992		—		—		226,290		5,823,282
Other international sales		959,548		224,868		178,004		4,850		1,367,270
Total	$	23,578,924	$	1,348,676	$	4,122,288	$	257,525	$	29,307,413

Schedule of earnings per share

The potential dilution, if any, is shown on the following schedule:


	Three Months Ended		Three Months Ended		Nine Months Ended		Nine Months Ended
	September 30, 2024		September 30, 2023		September 30, 2024		September 30, 2023
Net loss	$	(1,921,989)	$	(4,060,496)	$	(15,657,246)	$	(6,938,090)
Preferred stock dividend requirements		(57,611)		(58,111)		(172,832)		(174,335)
Loss applicable to common shareholders	$	(1,979,600)	$	(4,118,607)	$	(15,830,078)	$	(7,112,425)
Average common shares outstanding		29,937,159		29,937,159		29,937,159		29,937,159
Average common and common equivalent shares outstanding — diluted		29,937,159		29,937,159		29,937,159		29,937,159
Basic loss per share	$	(0.07)	$	(0.14)	$	(0.53)	$	(0.24)
Diluted loss per share	$	(0.07)	$	(0.14)	$	(0.53)	$	(0.24)